UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Approximations of the target-mediated drug disposition model and identifiability of model parameters

Journal of pharmacokinetics and pharmacodynamics, 2008-10, Vol.35 (5), p.573-591

2008

Volltextzugriff (PDF)

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

CPT: pharmacometrics and systems pharmacology, 2021-08, Vol.10 (8), p.914-927

2021

Volltextzugriff (PDF)

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate

Journal of pharmacokinetics and pharmacodynamics, 2022-06, Vol.49 (3), p.381-394

2022

Volltextzugriff (PDF)

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma

Pharmaceutical research, 2020-12, Vol.37 (12), p.252, Article 252

2020

Volltextzugriff (PDF)

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Cancer chemotherapy and pharmacology, 2020-09, Vol.86 (3), p.347-359

2020

Volltextzugriff (PDF)

Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies

Journal of pharmacokinetics and pharmacodynamics, 2024-08, Vol.51 (4), p.307-317

2024

Volltextzugriff (PDF)

Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

CPT: pharmacometrics and systems pharmacology, 2023-09, Vol.12 (9), p.1262-1273

2023

Volltextzugriff (PDF)

Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody

CPT: pharmacometrics and systems pharmacology, 2023-12, Vol.12 (12), p.2013-2026

2023

Volltextzugriff (PDF)

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors

CPT: pharmacometrics and systems pharmacology, 2022-10, Vol.11 (10), p.1358-1370

2022

Volltextzugriff (PDF)

Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis

Clinical and translational science, 2022-09, Vol.15 (9), p.2172-2183

2022

Volltextzugriff (PDF)

Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX

Clinical and translational science, 2023-12, Vol.16 (12), p.2744-2755

2023

Volltextzugriff (PDF)

Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

CPT: pharmacometrics and systems pharmacology, 2024-06, Vol.13 (6), p.1055-1066

2024

Volltextzugriff (PDF)

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

CPT: pharmacometrics and systems pharmacology, 2020-01, Vol.9 (1), p.48-59

2020

Volltextzugriff (PDF)

Inhaled innate immune ligands to prevent pneumonia

British journal of pharmacology, 2011-05, Vol.163 (1), p.195-206

2011

Volltextzugriff (PDF)

Target-mediated drug disposition model and its approximations for antibody–drug conjugates

Journal of pharmacokinetics and pharmacodynamics, 2014-02, Vol.41 (1), p.35-47

2014

Volltextzugriff (PDF)

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics

Expert opinion on drug metabolism & toxicology, 2009-07, Vol.5 (7), p.803-812

2009

Volltextzugriff (PDF)

Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site

Journal of pharmacokinetics and pharmacodynamics, 2017-10, Vol.44 (5), p.463-475

2017

Volltextzugriff (PDF)

Mathematical description of drug–target interactions: application to biologics that bind to targets with two binding sites

Journal of pharmacokinetics and pharmacodynamics, 2018-02, Vol.45 (1), p.23-34

2018

Volltextzugriff (PDF)

Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site

Journal of pharmacokinetics and pharmacodynamics, 2024-04

2024

Volltextzugriff (PDF)

Systemic exposures of gantenerumab: An integrated population pharmacokinetics (popPK) analysis across multiple clinical studies

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

Target-mediated drug disposition model for drugs that bind to more than one target

Journal of pharmacokinetics and pharmacodynamics, 2010-08, Vol.37 (4), p.323-346

2010

Volltextzugriff (PDF)

Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach

Journal of pharmacokinetics and pharmacodynamics, 2012-02, Vol.39 (1), p.5-16

2012

Volltextzugriff (PDF)

Target-mediated drug disposition model: relationships with indirect response models and application to population PK–PD analysis

Journal of pharmacokinetics and pharmacodynamics, 2009-08, Vol.36 (4), p.341-351

2009

Volltextzugriff (PDF)

Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.3135-3135

2023

Volltextzugriff (PDF)

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies

Clinical pharmacology and therapeutics, 2021-11, Vol.110 (5), p.1261-1272

2021

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(59)
Life Sciences & Biomedicine
(54)
Pharmacology & Pharmacy
(45)
Humans
(37)
Pharmacokinetics
(32)
Models, Biological
(25)
Pharmacology/toxicology
(24)
Male
(20)
Biochemistry
(19)
Biomedical And Life Sciences
(19)
Biomedicine
(19)
Pharmacy
(19)
Female
(18)
Monoclonal Antibodies
(18)
Biomedical Engineering And Bioengineering
(17)
Veterinary Medicine/veterinary Science
(15)
Target-Mediated Drug Disposition
(13)
Adult
(12)
Antibodies, Monoclonal - Pharmacokinetics
(10)
Computer Simulation
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Approximations of the target-mediated drug disposition model and identifiability of model parameters

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies

Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors

Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis

Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX

Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

Inhaled innate immune ligands to prevent pneumonia

Target-mediated drug disposition model and its approximations for antibody–drug conjugates

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics

Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site

Mathematical description of drug–target interactions: application to biologics that bind to targets with two binding sites

Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site

Systemic exposures of gantenerumab: An integrated population pharmacokinetics (popPK) analysis across multiple clinical studies

Target-mediated drug disposition model for drugs that bind to more than one target

Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach

Target-mediated drug disposition model: relationships with indirect response models and application to population PK–PD analysis

Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies

Suchergebnisse filtern